Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-7.32%
-1.99%
+0.14%
-3.06%
CRMD
CorMedix
$11.05
Login to see CorMedix (CRMD) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Earnings are forecast to grow
Trading below its fair value
Chart
$12.75 (-13.33%)
$11.22 (-1.52%)
$11.63 (-4.99%)
$10.49 (+5.34%)
CRMD has Moderate Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
CRMD overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Earnings increase YoY
Above analyst estimates
Rating
Rating
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Trading below its fair value
CRMD Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
CRMD Street view is bullish and have negative views on the near-term outlook
Average key support and resistance price levels.
Login to displayCRMD Earnings
The TTM reflects 12-month period, providing review of CRMD financial performance.
The company financial health has shown minor improvement, but significant issues remain
Financial Score
What is CRMD current stock price?
What are CRMD stock strengths?
What risks are associated with CRMD stock?
When is CRMD next earnings report?
What is CRMD market cap and volume?
What is CRMD's current Stock IQ?
Should I buy CRMD stock right now?
Is CRMD a Strong Buy right now?
What does a 'Strong Buy' rating mean for CRMD?
What does a 'Strong Sell' rating mean for CRMD?
What factors influence CRMD's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-7.32%
-1.99%
+0.14%
-3.06%
CRMD
CorMedix
Current Price
$11.05
Stock Insights
Strengths
Earnings are forecast to grow
Trading below its fair value
Login to unlock CorMedix (CRMD) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$12.75 (-13.33%)
$11.22 (-1.52%)
$11.63 (-4.99%)
$10.49 (+5.34%)
CRMD Analysts Opinion
CRMD Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Earnings increase YoY
Above analyst estimates
Rating
Rating
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Trading below its fair value
CRMD Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
CRMD Street view is bullish and have negative views on the near-term outlook
CRMD has Moderate Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
Average key support and resistance price levels.
Login to displayCRMD Earnings
The TTM data reflects the most recent 12-month period, providing overview of CRMD financial performance.
CRMD Financial Health
The company financial health has shown minor improvement, but significant issues remain
Financial Score
CRMD Latest Analysis
CorMedix files to sell 6.32M shares of common stock for holders.
Tue Sep 30, 2025
CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?. CorMedix and Mirum Pharmaceuticals are advancing niche therapies with strong launches rising sales and strategic acquisitions shaping their growth.
Tue Sep 23, 2025
Insider Decision Making Waves At Cormedix: Gregory Scott Duncan Exercises Options Realizing $45K. Highlighted on September 19 it was unveiled in an SEC filing that Duncan Director at ) executed a significant transaction involving the exercise of company stock options.United States Securities and Exchange Commission revealed that Duncan Director at Cormedix exercised stock options for 13333 shares of CRMD resulting in a transaction value of $45732.As of Friday morning Cormedix Inc is a biopharmac
Fri Sep 19, 2025
Major Exercise Alert: Beth Zelnick Kaufman Exercises Options Worth $495K At Cormedix. In a new SEC filing on September 12 it was revealed that Kaufman Chief Legal Officer at ) executed a significant exercise of company stock options.United States Securities and Exchange Commission Kaufman Chief Legal Officer at Cormedix executed a strategic derivative sale. This involved exercising stock options for 50000 shares of CRMD resulting in a transaction value of $495500.Cormedix Inc is a biopharmaceuti
Fri Sep 12, 2025
Strategic Sale: Elizabeth Hurlburt Decides To Exercise Options Worth $635K At Cormedix. In a new SEC filing on September 12 it was revealed that Hurlburt Chief Operating Officer at ) executed a significant exercise of company stock options.United States Securities and Exchange Commission Hurlburt Chief Operating Officer at Cormedix executed a strategic derivative sale. This involved exercising stock options for 53997 shares of CRMD resulting in a transaction value of $635004.Currently Cormedix I
Fri Sep 12, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
CRMD Stock trends
CRMD Stock performance
CRMD Stock analysis
CRMD investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings